Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
The new generation conjugate trastuzumab deruxtecan (Т-DXd) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have previously received a drug regimen containing anti-HER2 targeted agents, as well as for the treatment of adult patien...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2025-03-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1322 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|